⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2025

Supplemental Table 3 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Howard L. Li Soren Charmsaz Mari Nakazawa Stephanie Alden Madelena Brancati James M. Leatherman Ervin Griffin Hua‐Ling Tsai Nicole Groß Christopher J. Thoburn Alexei Hernandez Erin M. Coyne Sarah M. Shin Royce P. Lee Evan J. Lipson Burles A. Johnson Aliyah Pabani Yasser Ged Marina Baretti Julie R. Brahmer Jean Hoffman‐Censits Tanguy Y. Seiwert Daniel J. Zabransky Jennifer N. Durham Elizabeth M. Jaffee G. Scott Chandler Brittany L. Adler Won Jin Ho Chester Kao Mark Yarchoan

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study identifies distinct immune activation signatures associated with fatigue in cancer patients.
Early-on-treatment cohort characteristics highlight immune responses linked to fatigue experienced by patients.
Findings may suggest targeted approaches to manage fatigue during immune checkpoint inhibitor therapy.
Insights gained could help improve patient care and treatment outcomes for cancer patients facing fatigue.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals immune activation signatures linked to fatigue in cancer patients undergoing treatment.

Abstract

Supplemental Table 3 shows the characteristics of the early-on-treatment cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21847 https://doi.org/10.1158/2767-9764.30256032

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025 · 1 citations
2Supplemental Table 5 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025
3Supplemental Table 2 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025
4Supplemental Table 4 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025
5Supplemental Table 6 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025